66511-1-Ig

antibody from Proteintech Group

Targeting: MDM2 HDM2, MGC5370

Provider product page for 66511-1-Ig

Western blot

ELISA

Immunohistochemistry

Antibody data

Antibody Data
Antigen structure
References [23]
Comments [0]
Validations [0]

Submit

Product number: 66511-1-Ig - Provider product page
Provider: Proteintech Group
Product name: MDM2 antibody
Antibody type: Monoclonal
Description: MDM2 antibody (Cat. #66511-1-Ig) is a mouse monoclonal antibody that shows reactivity with Human, mouse, rat and has been validated for the following applications: IHC, WB, ELISA.
Reactivity: Human, Mouse, Rat
Host: Mouse
Conjugate: Unconjugated
Isotype: IgG
Antibody clone number: 2A6C9
Vial size: 20ul, 150ul

MDM2 protein structure - 66511-1-Ig shown in red.

Submitted references Mechanically stimulated osteocytes maintain tumor dormancy in bone metastasis of non-small cell lung cancer by releasing small extracellular vesicles.

Xie J, Xu Y, Liu X, Long L, Chen J, Huang C, Shao Y, Cai Z, Zhang Z, Zhou R, Leng J, Bai X, Song Q
eLife 2024 Mar 28;12

Licochalcone A alleviates ferroptosis in doxorubicin-induced cardiotoxicity via the PI3K/AKT/MDM2/p53 pathway.

Chen G, Luo S, Guo H, Lin J, Xu S
Naunyn-Schmiedeberg's archives of pharmacology 2024 Jun;397(6):4247-4262

Cordycepin Ameliorates Psoriasis-Like Skin Lesion by Regulating p53/MDM2 Feedback Loop.

Chen Y, Zhu C, Tai Z, Lian T, Zhu Q, Chen Z
Molecular biotechnology 2024 Jun 24;

CHEK2 knockout is a therapeutic target for TP53-mutated hepatocellular carcinoma.

Chen Y, Zhu Z, Wu X, Li H, Guan W, Ren H
Cell death discovery 2024 Jan 19;10(1):37

CircFSCN1 induces tumor progression and triggers epithelial-mesenchymal transition in bladder cancer through augmentation of MDM2-mediated p53 silencing.

Deng W, Chen R, Xiong S, Nie J, Yang H, Jiang M, Hu B, Liu X, Fu B
Cellular signalling 2024 Feb;114:110982

Searching for novel MDM2/MDMX dual inhibitors through a drug repurposing approach.

Li K, Hu W, Wang Y, Chen W, Wen H, Liu J, Li W, Wang B
Journal of enzyme inhibition and medicinal chemistry 2024 Dec;39(1):2288810

HSP105 suppresses the progression of cutaneous squamous cell carcinoma by activating the P53 signaling pathway.

Jia M, Zhou KY, Deng LJ, Fang S
American journal of cancer research 2023;13(7):3013-3026

Oryza sativa L. Indica Seed Coat Ameliorated Concanavalin A-Induced Acute Hepatitis in Mice via MDM2/p53 and PKCα/MAPK1 Signaling Pathways.

Zhao Z, Li Y, Guo S, Chen Y, Yin H, Li Y, Cheng G, Tian L
International journal of molecular sciences 2023 Sep 25;24(19)

LASS2 enhances p53 protein stability and nuclear import to suppress liver cancer progression through interaction with MDM2/MDMX.

Zhao Q, He W, Liu Z, Huang L, Yang X, Liu Y, Chen R, Min X, Yang Y
Cell death discovery 2023 Nov 14;9(1):414

hMOF induces cisplatin resistance of ovarian cancer by regulating the stability and expression of MDM2.

Cai M, Xu S, Jin Y, Yu J, Dai S, Shi XJ, Guo R
Cell death discovery 2023 Jun 8;9(1):179

EIF4A3-induced Circ_0001187 facilitates AML suppression through promoting ubiquitin-proteasomal degradation of METTL3 and decreasing m6A modification level mediated by miR-499a-5p/RNF113A pathway.

Yang X, Han F, Hu X, Li G, Wu H, Can C, Wei Y, Liu J, Wang R, Jia W, Ji C, Ma D
Biomarker research 2023 Jun 6;11(1):59

FAK inhibitor PF-562271 inhibits the migration and proliferation of high-grade serous ovarian cancer cells through FAK and FAK mediated cell cycle arrest.

Pan Q, Wang Q, Zhao T, Zhao X, Liang Y, Shi M, Chen C, Lin F
Medical oncology (Northwood, London, England) 2023 Jun 29;40(8):215

A novel polypeptide encoded by the circular RNA ZKSCAN1 suppresses HCC via degradation of mTOR.

Song R, Ma S, Xu J, Ren X, Guo P, Liu H, Li P, Yin F, Liu M, Wang Q, Yu L, Liu J, Duan B, Rahman NA, Wołczyński S, Li G, Li X
Molecular cancer 2023 Jan 23;22(1):16

Heliangin acts as a covalent ligand of RPS2 that disrupts pre-rRNA metabolic processes in NPM1-mutated acute myeloid leukemia.

Feng Y, Han Y, Hu A, Qu Y, Hu Y, Wu H, Wang X, He L
Acta pharmaceutica Sinica. B 2023 Feb;13(2):598-617

Loss of RanGAP1 drives chromosome instability and rapid tumorigenesis of osteosarcoma.

Gong Y, Zou S, Deng D, Wang L, Hu H, Qiu Z, Wei T, Yang P, Zhou J, Zhang Y, Zhu W, Xie X, Liao Z, Yang J, Zhang S, Liu A, Jiang Y, Zou Z, Bai X
Developmental cell 2023 Feb 6;58(3):192-210.e11

Flap endonuclease 1 Facilitated Hepatocellular Carcinoma Progression by Enhancing USP7/MDM2-mediated P53 Inactivation.

Bian S, Ni W, Zhu M, Zhang X, Qiang Y, Zhang J, Ni Z, Shen Y, Qiu S, Song Q, Xiao M, Zheng W
International journal of biological sciences 2022;18(3):1022-1038

A new FGF1 variant protects against adriamycin-induced cardiotoxicity via modulating p53 activity.

Xiao M, Tang Y, Wang J (a), Lu G, Niu J, Wang J (b), Li J, Liu Q, Wang Z, Huang Z, Guo Y, Gao T, Zhang X, Yue S, Gu J
Redox biology 2022 Feb;49:102219

Survivin suppression heightens BZML-induced mitotic catastrophe to overcome multidrug resistance by removing therapy-induced senescent A549/Taxol cells.

Bai Z, Zhou Y, Ye X, Li Y, Peng Y, Guan Q, Zhang W, Ma L
Biochimica et biophysica acta. Molecular cell research 2022 Feb;1869(2):119174

Hsa_circ_0005050 interacts with ILF3 and affects cell apoptosis and proliferation by disrupting the balance between p53 and p65.

Tan J, Sun M, Yin J, Zhou Q, Zhao R, Chen Q, Sun H, Jiang C, Li S, He Y
Chemico-biological interactions 2022 Dec 1;368:110208

Long noncoding RNA CERS6-AS1 modulates glucose metabolism and tumor progression in hepatocellular carcinoma by promoting the MDM2/p53 signaling pathway.

Xu B, Wei Y, Liu F, Li L, Zhou S, Peng Y, Li B
Cell death discovery 2022 Aug 4;8(1):348

Ubiquitin-specific protease 7 mediates platelet-derived growth factor-induced pulmonary arterial smooth muscle cells proliferation.

Zhu Y, Zhang Q, Yan X, Liu L, Zhai C, Wang Q, Chai L, Li M
Pulmonary circulation 2021 Oct-Dec;11(4):20458940211046131

LncRNA MIAT enhances cerebral ischaemia/reperfusion injury in rat model via interacting with EGLN2 and reduces its ubiquitin-mediated degradation.

Li S, Fu J, Wang Y, Hu C, Xu F
Journal of cellular and molecular medicine 2021 Nov;25(21):10140-10151

MeCP2 facilitates breast cancer growth via promoting ubiquitination-mediated P53 degradation by inhibiting RPL5/RPL11 transcription.

Tong D, Zhang J, Wang X, Li Q, Liu LY, Yang J, Guo B, Ni L, Zhao L, Huang C
Oncogenesis 2020 Jun 1;9(5):56

No comments: Submit comment

No validations: Submit validation data